Dermoscopic Evaluation of Melanocytic Nevi Changes With Combined Mitogen-Activated Protein Kinase Pathway Inhibitors Therapy for Melanoma

JAMA Dermatol. 2016 Oct 1;152(10):1162-1164. doi: 10.1001/jamadermatol.2016.2426.
No abstract available

Publication types

  • Letter
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azetidines / adverse effects*
  • Azetidines / therapeutic use*
  • Cell Transformation, Neoplastic / chemically induced*
  • Dermoscopy*
  • Female
  • Humans
  • Indoles / adverse effects*
  • Indoles / therapeutic use*
  • Male
  • Melanoma / chemically induced*
  • Melanoma / drug therapy*
  • Middle Aged
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • Nevus, Pigmented / drug therapy*
  • Nevus, Pigmented / pathology*
  • Piperidines / adverse effects*
  • Piperidines / therapeutic use*
  • Signal Transduction / drug effects*
  • Skin Neoplasms / chemically induced*
  • Skin Neoplasms / drug therapy*
  • Sulfonamides / adverse effects*
  • Sulfonamides / therapeutic use*
  • Vemurafenib

Substances

  • Azetidines
  • Indoles
  • Piperidines
  • Sulfonamides
  • Vemurafenib
  • Mitogen-Activated Protein Kinases
  • cobimetinib